Santhera Pharmaceuticals has announced plans to submit an application for Conditional Approval for Puldysa (also known as idebenone and Raxone) for …
Santhera announces plans to apply for conditional approval for PuldysaRead More

29 March 2019 by abzali123
Santhera Pharmaceuticals has announced plans to submit an application for Conditional Approval for Puldysa (also known as idebenone and Raxone) for …
Santhera announces plans to apply for conditional approval for PuldysaRead More

28 March 2019 by abzali123
In a press release earlier, Sarepta Therapeutics announced results of an interim analysis of the casimersen part of their late stage, phase 3 ESSENCE …
Sarepta Therapeutics announces preliminary results in casimersen (exon 45 skipping) trialRead More

26 March 2019 by abzali123
A recently published study has found that boys treated with daily Deflazacort (a corticosteroid) have more fractures than boys treated with other …

25 March 2019 by abzali123
We are delighted to announce that television and radio broadcaster Jonny Gould has become an ambassador for Action Duchenne. Jonny is a presenter and …
Jonny Gould becomes an Ambassador for Action DuchenneRead More
20 March 2019 by abzali123

19 March 2019 by abzali123
We are delighted to announce our friends and long-time supporters of the charity, Trevor and Lucy, are our new Action Duchenne Ambassadors! Lucy …
Trevor and Lucy become Ambassadors for Action DuchenneRead More

26 February 2019 by abzali123
Raxone (also known as Idebenone) is a drug produced by Santhera Pharmaceuticals, which treats several conditions and has the potential to treat …

26 February 2019 by abzali123
In a press release, Santhera Pharmaceuticals has announced results from the SYROS study, where long-term treatment with idebenone (also known as …

15 February 2019 by abzali123
This weekend our Director of Research, Neil Bennett, and our CEO, Shelley Simmonds, are in Rome attending the Duchenne Parent Project International …

14 February 2019 by abzali123
Last weekend, our wonderful supporters Stoke By Nayland Golf Club held their much anticipated raffle draw. The prize was a week in a luxury villa …

12 February 2019 by abzali123
Solid Biosciences have announced preliminary data from their phase 1/2 IGNITE-DMD clinical trial that is testing the safety and effectiveness of …
Solid Biosciences announce preliminary trial resultsRead More

6 February 2019 by abzali123
PTC Therapeutics had their annual kick-off meeting in Cascais, outside of Lisbon from 28th January to the 1st of February. Cormac Fegan, age 8, and …
Action Duchenne
2nd Floor
South
One Castle Park
Tower Hill
Bristol
BS2 OJA
0300 102 1762
info@actionduchenne.org
